featured
2020 Top Stories in Oncology: The New Binding Pocket on BCR/ABL and Phase III Results of the New CML Drug Binding There
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- A Hochhaus, C Boquimpani, D Rea, et al. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs). Paper presented at: 62nd ASH Annual Meeting and Exposition; December 5–8, 2020. Abstract LBA-4.
- Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med. 2019;381(24):2315-2326.
- Manley PW, Barys L, Cowan-Jacob SW, et al. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res 98:106.
Disclosure statements are available on the authors' profiles: